Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBridge Biosciences (NBP) Total Current Liabilities (2018 - 2022)

NovaBridge Biosciences (NBP) has disclosed Total Current Liabilities for 5 consecutive years, with $106.6 million as the latest value for Q4 2022.

  • Quarterly Total Current Liabilities rose 9.22% to $106.6 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $106.6 million through Dec 2022, up 9.22% year-over-year, with the annual reading at $109.9 million for FY2022, 12.26% up from the prior year.
  • Total Current Liabilities for Q4 2022 was $106.6 million at NovaBridge Biosciences, up from $97.6 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $106.6 million in Q4 2022, with the low at $50.1 million in Q4 2018.
  • Average Total Current Liabilities over 5 years is $84.9 million, with a median of $86.9 million recorded in 2020.
  • The sharpest move saw Total Current Liabilities skyrocketed 66.77% in 2019, then grew 4.12% in 2020.
  • Over 5 years, Total Current Liabilities stood at $50.1 million in 2018, then skyrocketed by 66.77% to $83.5 million in 2019, then rose by 4.12% to $86.9 million in 2020, then rose by 12.27% to $97.6 million in 2021, then increased by 9.22% to $106.6 million in 2022.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $106.6 million, $97.6 million, and $86.9 million for Q4 2022, Q4 2021, and Q4 2020 respectively.